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Background:  Previous studies demonstrated that low-density lipoprotein cholesterol (LDL-C) is “lower the better” in patients with coronary artery 
disease. Ezetimibe, an intestinal cholesterol-absorption inhibitor, can reduce LDL-C when added to standard dose of statin treatment but the effect 
for endothelial function of this combination therapy is not well elucidated.
Methods:  We investigated 140 patients with stable coronary artery disease in single center, prospective, randomized controlled, open-labeled 
trial (UMIN registration No. UMIN 000002297) comparing treatment with doubling the dose of atorvastatin (A20; n=70) to adding the ezetimibe 
(A10E10; n=70). We used reactive hyperemia peripheral artery tonometry to assessing endothelial function as the natural logarithmic scaled reactive 
hyperemia index (L_RHI). High sensitive C-reactive protein, remant-like particles-cholesterol, malondialdehyde-modified LDL were also measured.
Results:  Although LDL-C significantly lowered in both groups (P<0.001, respectively), the lowering rate is higher in A10E10 group compared to A20 
group (-24±13% vs -8.2±16%, P<0.05). High sensitive C-reactive protein, remant-like particles-cholesterol, malondialdehyde-modified LDL were also 
significantly lowered in both groups (P<0.05, respectively). L_RHI, which is primary endpoint of this study, is significantly increased in A20 group 
(0.480±0.249 to 0.644±0.256; P<0.001) and whereas no significant change in A10E10 group (0.481±0.270 to 0.526±0.252; P=0.29).
Conclusion: Only doubling the dose of statin therapy improved endothelial function, and adding the ezetimibe therapy does not despite more 
reducing LDL-C and other cholesterol parameters. This indicates pleiotropic effect of statin which is independent from cholesterol lowering effect, 
and we have to increase dose of statin to improve endothelial function.
